  With the emergence and spread of infectious diseases with pandemic potential,
such as COVID- 19, the urgency for vaccine development have led to
unprecedented compressed and accelerated schedules that shortened the standard
development timeline. In a relatively short time, the leading pharmaceutical
companies1, received an Emergency Use Authorization (EUA) for vaccine\prime s
en-mass deployment To monitor the potential side effect(s) of the vaccine
during the (initial) vaccination campaign, we developed an optimal sequential
test that allows for the early detection of potential side effect(s). This test
employs a rule to stop the vaccination process once the observed number of side
effect incidents exceeds a certain (pre-determined) threshold. The optimality
of the proposed sequential test is justified when compared with the ({\alpha},
{\beta}) optimality of the non-randomized fixed-sample Uniformly Most Powerful
(UMP) test. In the case of a single side effect, we study the properties of the
sequential test and derive the exact expressions of the Average Sample Number
(ASN) curve of the stopping time (and its variance) via the regularized
incomplete beta function. Additionally, we derive the asymptotic distribution
of the relative savings in ASN as compared to maximal sample size. Moreover, we
construct the post-test parameter estimate and studied its sampling properties,
including its asymptotic behavior under local-type alternatives. These limiting
behavior results are the consistency and asymptotic normality of the post-test
parameter estimator. We conclude the paper with a small simulation study
illustrating the asymptotic performance of the point and interval estimation
and provide a detailed example, based on COVID-19 side effect data (see Beatty
et al. (2021)) of our suggested testing procedure.
